PHASE-I CLINICAL AND PHARMACOKINETIC TRIAL OF BREQUINAR SODIUM (DUP 785 NSC 368390)

  • 15 August 1989
    • journal article
    • research article
    • Vol. 49  (16) , 4648-4653
Abstract
Brequinar sodium is a 4-quinolinecarboxylic acid analogue that inhibits dihydrooroate dehydrogenase and subsequent de novo pyrimidine biosynthesis. It has shown dose-dependent antineoplastic activity against several mouse and human tumor models. This trial evaluated Brequinar given as a single daily i.v. bolus over a 5-day period repeated every 28 days. One hundred seven courses of treatment at dosages ranging from 36 to 300 mg/m2/day .times. 5 were administered to 45 patients (31 male and 14 female) with refractory solid tumors median age was 58 years (range 30-74); median Southwest Oncology Group performance status were 1 (range, 0-3). Thirty patients had prior cytotoxic chemotherapy. Dose-limiting toxicities were thrombocytopenia and a severe desquamative maculopapular dermatitis. Two of 5 good risk patients at 300 mg/m2 and 3 of 6 poor risk patients at 170 mg/m2 developed a platelet count < 25 .times. 103/.mu.L. Two of 5 good risk patients at 300 mg/m2 and 1 of 6 poor risk patients at 170 mg/m2 developed a severe desquamative dermatitis. Moderate to severe mucositis was usually associated with the thrombocytopenia and/or the dermatitis. Nonhematological drug-related toxicities included nausea and vomiting, malaise, anorexia, diarrhea, phlebitis, reversible transaminase elevation, and mucositis. Other hematological toxicities were anemia, granulocytopenia, and leukopenia. There were no drug-related deaths. There were no objective tumor responses. Plasma and urine levels of Brequinar were quantified by high pressure liquid chromatography in 28 patients. Plasma levels and areas under the curve increased proportionally with increased dose. Brequinar had a harmonic mean terminal t1/2 of 8.1 .+-. 3.6 h with a model-independent determined apparent volume of distribution at steady state of 9.0 7U 2.9 liters/m2 and a total body clearance of 19.2 .+-. 7.7 ml/min/m2. Renal excretion was a minor route of elimination for Brequinar. The maximally tolerated dose of Brequinar on a daily .times. 5 i.v. schedule was 250 mg/m2 for good risk patients. For the daily .times. 5 i.v. schedule, the recommended dose of Brequinar for phase II evaluation is 250 mg/m2 for good risk patients and 135 mg/m2 for poor risk patients.